Andrew John  Partridge net worth and biography

Andrew Partridge Biography and Net Worth

Andrew Partridge serves as executive vice president and chief commercial officer. Mr. Partridge has more than 20 years of global pharmaceutical sales and marketing experience leading more than 20 commercial launches across multiple indications, including oncology, hematology and rare diseases.

Prior to joining Turning Point Therapeutics, Mr. Partridge was both chief operating officer and chief commercial officer of Centrexion Therapeutics, a privately held biotech. He was previously with Vertex Pharmaceuticals for 5 years, most recently as senior vice president and head of North American commercial operations where he built the team to successfully launch multiple cystic fibrosis therapies and new indications. Mr. Partridge had overall responsibility at Vertex across the U.S. and Canada for marketing, sales, market access and patient services and led the cross-functional North American leadership team that included medical affairs, finance, legal and human resources. In the preceding 20 years, he served in sales and marketing roles of increasing responsibility with Schering-Plough, Roche and Amgen. At Amgen, he held senior marketing and sales roles for oncology and hematology therapeutics, including strategic planning and operations of the $5 billion oncology business unit, and therapeutic area head for oncology in global strategic marketing. His global experience also includes marketing and sales management roles based in the U.K. at Roche and Schering-Plough focused on oncology and hematology. He earned a Higher National Diploma in Medical Laboratory Sciences from Birmingham City University in the U.K.

What is Andrew John Partridge's net worth?

The estimated net worth of Andrew John Partridge is at least $1.65 million as of July 14th, 2021. Mr. Partridge owns 21,767 shares of Turning Point Therapeutics stock worth more than $1,654,510 as of April 20th. This net worth evaluation does not reflect any other investments that Mr. Partridge may own. Learn More about Andrew John Partridge's net worth.

How do I contact Andrew John Partridge?

The corporate mailing address for Mr. Partridge and other Turning Point Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Turning Point Therapeutics can also be reached via phone at (858) 926-5251 and via email at [email protected]. Learn More on Andrew John Partridge's contact information.

Has Andrew John Partridge been buying or selling shares of Turning Point Therapeutics?

Andrew John Partridge has not been actively trading shares of Turning Point Therapeutics during the past quarter. Most recently, Andrew John Partridge sold 1,869 shares of the business's stock in a transaction on Wednesday, July 14th. The shares were sold at an average price of $74.90, for a transaction totalling $139,988.10. Following the completion of the sale, the executive vice president now directly owns 21,767 shares of the company's stock, valued at $1,630,348.30. Learn More on Andrew John Partridge's trading history.

Who are Turning Point Therapeutics' active insiders?

Turning Point Therapeutics' insider roster includes Mark Alles (Director), Brian Baker (SVP), Athena Countouriotis (CEO), Jingrong Cui (Director), Mohammad Hirmand (EVP), Annette North (EVP), Andrew Partridge (EVP), Siegfried Reich (EVP), and Paolo Tombesi (CFO). Learn More on Turning Point Therapeutics' active insiders.

Andrew John Partridge Insider Trading History at Turning Point Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/14/2021Sell1,869$74.90$139,988.1021,767View SEC Filing Icon  
See Full Table

Andrew John Partridge Buying and Selling Activity at Turning Point Therapeutics

This chart shows Andrew John Partridge's buying and selling at Turning Point Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Turning Point Therapeutics Company Overview

Turning Point Therapeutics logo
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $76.01
Low: $76.01
High: $76.01

50 Day Range

MA: $75.83
Low: $74.80
High: $76.01

2 Week Range

Now: $76.01
Low: $23.77
High: $82.20

Volume

4,322 shs

Average Volume

1,137,726 shs

Market Capitalization

$3.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A